Health Condition 1: N72- Inflammatory disease of cervix uteri
Conditions
Interventions
Intervention1: Vitamin D3: Vitamin D3 60,000 IU will be given once a week for a total duration of 8 weeks. The enrolled patients will be assessed at baseline, 4 weeks and 8 weeks for WaLIDD score, Vis
Sponsors
Pt BD Sharma PGIMS Rohtak
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients falling between the age group of 14 – 40 years. 2. Patients with painful and relatively regular menstruation lasting 3-7 days for at least 4 consecutive painful periods in recent six cycles. 3. Patient or legal guardian willing to provide written informed consent. 4. Patients with Visual Analogue pain score of more than equal to 45mm. 5. Patients with serum vitamin D levels
Exclusion criteria
Exclusion criteria: 1. Patients diagnosed with secondary dysmenorrhea due to uterine disorders (like fibroid, polyps, endometrial hypertrophy and endometriosis) and ovarian disorders (ovarian cysts and polycystic ovaries). 2. History of- • Abnormal vaginal and cervical secretions. • Epilepsy, cardiovascular, hepatic or kidney diseases. • Any mental illness and drug use. • Significant gastrointestinal or genitourinary procedure. • Any endocrine procedure. • Any abdominal or pelvic surgery. • Thyroid disorders. 3. Ongoing treatment with- • Anticoagulants. • Hormonal contraceptives. • Mineral or vitamin supplementation in the past 3 months. 4. Any allergic reactions to the study drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Decrease in WaLIDD score. 2. Improvement in pain intensity by using the Visual Analogue Scale (VAS). 3. Improvement in serum Vitamin D3 levels at baseline and 8 weeks and its correlation with decrease in WaLIDD score and improvement as per VAS. 4. Number of analgesic medications used.Timepoint: Participants will be assessed initially during enrollment for baseline parameters and will be followed up at 4 weeks and 8 weeks for assessment of WaLIDD score, VAS score, number of analgesics used and serum Vitamin D3 levels will be assessed at baseline and 8 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Improvement in quality of life, by using SF-36 questionnaire. 2. Relief in menstrual bleeding using Pictorial Blood Loss Assessment Chart. Timepoint: Participants will be assessed initially during baseline parameters and will be followed up at 4 weeks and 8 weeks for assessment of Health related quality of life and Pictorial blood loss assessment chart score. | — |
Countries
India
Contacts
Public ContactDr Kanchan Kalra
Pt B. D Sharma PGIMS, Rohtak
Outcome results
None listed